Skip to content
Menu

Astellas Pharma Inc. ALPMY

Full chart Compare
Set alert

Price alert · ALPMY

All alert types
16.90 USD -0.05 (-0.29%)

As ofNov 17, 2026, 3:59 PM EST

16.52 Day range 17.05
12.12 52-week range 17.35
YTD
+27.16%
1 year
+39.21%

Included in Essentials and up

Sign in to see Fair value

Discounted cash flow estimates against the price, and the P/E against its industry and sector.

Included in Essentials and up

Sign in to see Head count and owner earnings

Employees by annual report and the cash the business earns for its owners.

Included in Essentials and up

Sign in to see P/E against peers

The price to earnings ratio beside the closest competitors and their median.

Included in Essentials and up

Sign in to see Cash flow and returns

How profit turns into free cash flow, and the returns on equity, assets and capital.

Financial health

Altman Z-Score

3.63 Safe zone

Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.

Piotroski F-Score

8 / 9 Strong

Nine pass/fail tests of profitability, leverage and efficiency.

Rating

A+4 / 5 overall

  • DCF 5
  • Return on Equity 5
  • Return on Assets 5
  • Debt / Equity 3
  • P/E 3
  • P/B 3

Valuation

P/E 14.9×
P/S 2.0×
P/B 2.5×
P/FCF 8.6×
EV/EBITDA 7.2×
EV/Sales 2.0×
FCF Yield 11.7%

Profitability

Gross Margin 74.6%
Operating Margin 19.6%
Net Margin 13.6%
ROE 16.8%
ROIC 13.2%
ROA 8.6%

Growth (YoY)

Revenue 18.6%
Operating Income 984.4%
EPS (diluted) 511.0%
Free Cash Flow 293.1%

Financial Health

Current Ratio 1.2×
Quick Ratio 0.9×
Debt / Equity 0.1×
Net Debt / EBITDA -0.1×
Interest Coverage 29.8×

Dividends

Dividend Yield 3.1%
Payout Ratio 46.7%

Annual · latest fiscal year ends 2026-03-31